Pull the Other One, Class Tells Obesity Firm

LOS ANGELES (CN) - A class action claims the Obesity Research Institute pushes its "Lipozene" drug with false claims that it is a "miracle ... weight loss breakthrough" that "is clinically proven" to "cause rapid and substantial weight loss without the need of diet and exercise." Obesity allegedly claims, falsely, that Lipozene will "attack just the fat" and that 78% of all the weight lost is "pure body fat."

"In point of fact, Lipozene is nothing more than a fiber pill that has no weight loss properties," the class claims in Superior Court. It says Henry den Uijl founded the defendants company in 2003 in California.

Plaintiffs are represented by Milstein, Adelman & Kreger.

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Email *

Submit